Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the ...

Analysts, who are highly bullish on the stock, have fretted for some time that Viking needed a partner to actually make the ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid ...

The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched ...

After Viking Therapeutics (VKTX) announced a multi-year manufacturing agreement with CordenPharma to support the commercialization of VK2735, ...

CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is being developed in both oral and subcutaneous ...